(A) Specificity of FVIIa neoantigen specific capture antibody. Human FVII (ERL) (⋄), human FVII (ERL) activated with commercial factor Xa (□), and recombinant FVIIa (NovoNordisk) (•). The ELISA was performed using a tag antibody directed to FVII labeled with peroxidase (ERL), as amplification of the FVIIa signal was not necessary. (B) Western blot analysis of FVIIa neoantigen specific capture antibody. Lane A, human FVII (ERL); lane B, recombinant FVIIa (NovoNordisk); lane C, human FVIIa (ERL); lane D, human FVII (ERL) activated by factor Xa. Human FVIIa from ERL is des-Gla and has a reduced molecular weight. Initial electrophoresis was performed with samples that were not reduced (Non-Reducing) and that were reduced with dithiothreitol.